Special Issue "Interferons"

Quicklinks

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (30 November 2009)

Special Issue Editor

Guest Editor
Dr. Howard A. Young
Principal Investigator & Deputy Lab Chief, Laboratory of Experimental Immunology, Cancer and Inflammation Program, Center for Cancer Research, Frederick National Laboratory for Cancer Research, Bldg. 560/31-23, Chandler Street, Frederick, MD 21702-1201, USA
E-Mail: younghow@mail.nih.gov
Phone: +1 301 846 5700
Fax: +1 301 846 1673
Interests: interferon-gamma; post transcriptional regulation; NK cells; interleukins

Special Issue Information

Dear Colleagues,

This issue of Pharmaceuticals will focus on the pre-clinical and clinical biology of the interferons including how the interferons affect and alter the biological responses of the host in conditions of autoimmunity, infectious diseases and cancer.

Howard A. Young, Ph. D.
Guest Editor

Keywords

  • interferon
  • interleukins
  • pre-clinical models
  • clinical applications
  • STAT
  • receptors
  • gene induction
  • cancer
  • autoimmunity
  • infectious diseases

Published Papers (7 papers)

by  and
Pharmaceuticals 2010, 3(4), 1162-1186; doi:10.3390/ph3041162
Received: 9 March 2010; in revised form: 3 April 2010 / Accepted: 12 April 2010 / Published: 20 April 2010
Show/Hide Abstract | Cited by 4 | PDF Full-text (203 KB) | HTML Full-text | XML Full-text

by
Pharmaceuticals 2010, 3(4), 1108-1121; doi:10.3390/ph3041108
Received: 25 January 2010; in revised form: 19 March 2010 / Accepted: 1 April 2010 / Published: 14 April 2010
Show/Hide Abstract | PDF Full-text (244 KB) | HTML Full-text | XML Full-text

by , , ,  and
Pharmaceuticals 2010, 3(4), 994-1015; doi:10.3390/ph3040994
Received: 2 March 2010; in revised form: 15 March 2010 / Accepted: 29 March 2010 / Published: 30 March 2010
Show/Hide Abstract | Cited by 19 | PDF Full-text (588 KB) | HTML Full-text | XML Full-text

by , ,  and
Pharmaceuticals 2010, 3(4), 795-809; doi:10.3390/ph3040795
Received: 5 February 2010; in revised form: 24 March 2010 / Accepted: 24 March 2010 / Published: 25 March 2010
Show/Hide Abstract | Cited by 1 | PDF Full-text (1337 KB) | HTML Full-text | XML Full-text
abstract graphic

by ,  and
Pharmaceuticals 2010, 3(2), 406-418; doi:10.3390/ph3020406
Received: 10 December 2009; in revised form: 28 January 2010 / Accepted: 1 February 2010 / Published: 4 February 2010
Show/Hide Abstract | PDF Full-text (1015 KB) | HTML Full-text | XML Full-text

by , ,  and
Pharmaceuticals 2010, 3(2), 323-344; doi:10.3390/ph3020323
Received: 1 December 2009; in revised form: 20 January 2010 / Accepted: 25 January 2010 / Published: 28 January 2010
Show/Hide Abstract | Cited by 3 | PDF Full-text (337 KB) | HTML Full-text | XML Full-text

by  and
Pharmaceuticals 2009, 2(3), 206-216; doi:10.3390/ph2030206
Received: 13 November 2009; in revised form: 2 December 2009 / Accepted: 7 December 2009 / Published: 15 December 2009
Show/Hide Abstract | PDF Full-text (164 KB) | HTML Full-text | XML Full-text

Last update: 4 March 2014

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert